Short answer
Revvity (RVTY) filed its Q3 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jul 5, 2026. Quarterly revenue was $730M (up 1.3% year over year) with net income of $52M.
Q3 2026 key financials · XBRL
- Revenue
- $730M
- +1.3% YoY · +2.6% QoQ
- Net income
- $52M
- −3.9% YoY · +27.3% QoQ
- Operating margin
- 12.2%
- EPS (diluted)
- $0.46
- +0.0% YoY · +27.8% QoQ
Source: XBRL data from the Revvity (RVTY) Q3 2026 10-Q on SEC EDGAR. USD.
Revvity Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $729.7M, up $9.4M or 1% YoY
- Diagnostics strongest segment, revenue $371.0M, up $16.6M or 5% YoY
- Life Sciences weakest segment, revenue $358.7M, down $7.2M or 2% YoY
- Gross margin 57.1% vs 54.5%; operating margin 12.2% vs 12.6% YoY
- Cash $1,022.9M; operating cash flow $317.8M for six months, up $49.4M YoY
- Outlook: internal operations expected to fund expenses, acquisitions, debt service and dividends for at least 12 months; tariff-recovery timing remains uncertain
Risk Factors
- Government funding and regulatory uncertainty: recently proposed U.S. changes have made customers more cautious on instrumentation and consumable purchases
- AI deployment: evolving cybersecurity, intellectual-property, privacy, and data-protection rules create potential liability and regulatory action
- Near-term demand: pharmaceutical, biotechnology, and research customers may delay purchases amid funding uncertainty and restricted capital spending
- Supply-chain disruption: limited or single-source suppliers could cause higher prices, quality declines, or delivery delays
- Intangible-asset impairment: $8.8 billion of net intangible assets exposed to adverse valuation changes or slower Life Sciences and Diagnostics growth
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Revvity quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.